Details of the Drug Combination

General Information of Drug Combination (ID: DCRR8RL)

Drug Combination Name

Ridaforolimus SCH-900776

Indication

Disease Entry	Status	REF
Large cell lung carcinoma	Investigative	[1]

Component Drugs

Ridaforolimus DMLHEU7

SCH-900776 DM67EMK

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: NCI-H460

Zero Interaction Potency (ZIP) Score: 3.75

Bliss Independence Score: 8.72

Loewe Additivity Score: 6.01

LHighest Single Agent (HSA) Score: 10.46

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Ridaforolimus

Disease Entry	ICD 11	Status	REF
Sarcoma	2A60-2C35	Phase 3	[2]

Ridaforolimus Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Serine/threonine-protein kinase mTOR (mTOR)	TTCJG29	MTOR_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

Indication(s) of SCH-900776

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]

SCH-900776 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Checkpoint kinase-1 (CHK1)	TTTU902	CHK1_HUMAN	Inhibitor	[5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Colon carcinoma	DCWZ7WW	RKO	Investigative	[6]
Rectal adenocarcinoma	DCESKXL	SW837	Investigative	[6]
Adenocarcinoma	DCK3IF8	COLO320DM	Investigative	[1]
Adenocarcinoma	DCPML0E	HCT116	Investigative	[1]
Germ cell tumour	DC6TMI8	PA1	Investigative	[1]
Malignant melanoma	DCUABO8	A375	Investigative	[1]
Malignant melanoma	DCFM6EN	RPMI7951	Investigative	[1]
Ovarian endometrioid adenocarcinoma	DCZZMXP	A2780	Investigative	[1]
Ovarian serous cystadenocarcinoma	DCZOY5B	SK-OV-3	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 DrugCom(s)

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7884).
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7943).
4	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
5	Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
6	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.